Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIVIG: IGIV-C in Relapsing-Remitting Multiple Sclerosis
NCT00220779Phase 2Completed
- Sponsor
- Grifols
- Start
- Dec 2002
- Primary completion
- Feb 2005
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of intravenous human immunoglobulin in relapsing-remitting multiple sclerosis (RRMS), sponsored by Grifols. Started Dec 2002; status: completed.
02
Drugs
intravenous human immunoglobulin
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00220779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220779.